Exelixis announces settlement of dispute with Genentech
Exelixis announced a settlement of the company’s dispute with Genentech concerning their collaboration for development and commercialization of cobimetinib, marketed as COTELLIC®. The companies entered into an amendment to revise the revenue and cost-sharing arrangements for the collaboration. July 20, 2017